If you’ve spent any time in cosmetic ingredient forums or formulation meetings, you’ve almost certainly heard of dipeptide diaminobutyroyl benzylamide diacetate — the peptide sold under the trade name Syn-Ake. It’s been around for a while now, and the “snake venom peptide” marketing angle still grabs attention. But after years of working with peptide actives, I think it’s time to look past the marketing copy and dig into what the actual research tells us — what Syn-Ake does at the cellular level, what results you can honestly expect, and how it compares to other topical options like Argireline.
What Exactly Is Dipeptide Diaminobutyroyl Benzylamide Diacetate?
Syn-Ake (INCI: Dipeptide Diaminobutyroyl Benzylamide Diacetate) is a short synthetic peptide modeled after waglerin-1, a tripeptide from the venom of the temple viper, Tropidolaemus wagleri. In nature, waglerin-1 blocks nicotinic acetylcholine receptors at the neuromuscular junction — that’s how the snake’s venom paralyzes prey.
The cosmetic ingredient borrows that concept but in a much gentler form. The peptide sequence is H-β-Ala-Pro-Dab-NH-Bzl, and rather than targeting nicotinic receptors, it acts as a muscarinic acetylcholine receptor (mAChR) antagonist. That distinction is worth understanding — it’s a big part of why dipeptide diaminobutyroyl benzylamide diacetate can modulate muscle contraction without the risks you’d associate with actual neurotoxins.
| Property | Detail |
|---|---|
| INCI Name | Dipeptide Diaminobutyroyl Benzylamide Diacetate |
| Trade Name | Syn-Ake (Pentapharm/Lubrizol) |
| CAS Number | 823202-99-9 |
| Molecular Formula | C₂₃H₃₇N₅O₇ |
| Molecular Weight | 495.6 g/mol |
| Peptide Sequence | H-β-Ala-Pro-Dab-NH-Bzl |
| Mechanism | mAChR antagonist (synthetic snake venom peptide) |
| Typical Use Level | 0.5–5% in finished formulations |
| Solubility | Water-soluble |
Dipeptide Diaminobutyroyl Benzylamide Diacetate: Mechanism of Action
To make sense of how Syn-Ake works on wrinkles, you need to start with the basics of neuromuscular signaling. When your brain tells a facial muscle to contract, it releases acetylcholine (ACh) at the neuromuscular junction. This neurotransmitter binds to receptors on the muscle cell — nicotinic receptors (nAChRs) for direct activation, and muscarinic receptors (mAChRs) for modulatory signals. Either way, the muscle contracts.
Do this thousands of times over the years, and you get expression lines — crow’s feet, forehead creases, the “elevens” between your brows. Botox handles this by cleaving SNAP-25, which flat-out prevents ACh from being released. Effective? Absolutely. But it’s also a medical procedure with real risks and a price tag to match.
Syn-Ake works differently. Instead of stopping ACh release, this synthetic snake venom peptide binds to the muscarinic acetylcholine receptors on the muscle cell surface. It acts as a competitive antagonist — basically sitting in the receptor’s “seat” so ACh can’t bind as effectively. The result? The muscle contraction signal gets toned down. Not shut off, just… quieter. Over weeks of daily application, the reduced contraction intensity starts to show up as softer expression lines.
Pentapharm’s original in vitro work showed Syn-Ake inhibiting muscle cell contractions by up to 82% at 0.5 mM within 2 hours. The IC₅₀ for dipeptide diaminobutyroyl benzylamide diacetate muscle contraction inhibition came in around 0.05 mM — that’s genuinely potent for something you’re just applying topically. But keep in mind: in vitro muscle cells in a dish are a long way from someone’s actual face. The in vitro data tells you the mechanism is real, but the clinical data tells you what you can actually see.
Clinical Evidence: Anti-Wrinkle Efficacy
The study everyone cites for dipeptide diaminobutyroyl benzylamide diacetate anti-wrinkle efficacy is the Pentapharm 28-day trial:
- Setup: 45 volunteers, double-blind, placebo-controlled. Applied a cream with 4% Syn-Ake twice daily for 28 days.
- Results: Average wrinkle depth dropped by 21%, wrinkle surface area by 20%. The placebo group changed less than 3%.
- Timeline: Measurable improvements showed up by day 7 and kept progressing through day 28.
- Measurement: Silicone replicas analyzed by fringe projection — a standard validated method for this kind of work.
Another study testing Syn-Ake at different concentrations found that 4% gave the best results, 1% still did something meaningful, and above 5%, you hit diminishing returns. That aligns with the 0.5–5% use range most formulators recommend.
Now, is 21% wrinkle reduction impressive? I’d say it’s respectable for a topical peptide — it’s in the same ballpark as Argireline’s reported numbers. But let’s be honest about the comparison: Botox routinely delivers 60–80% reduction in glabellar line severity. Syn-Ake and Argireline play in a completely different league. Whether that league is “worth it” depends on what your formulation is trying to achieve.
Syn-Ake vs Argireline: Which One Should You Pick?
This is the question I get asked most. These two are the heavyweights of the topical anti-wrinkle peptide world, and they approach the problem from totally different angles. Here’s how syn-Ake vs Argireline breaks down in practice:
| Parameter | Syn-Ake | Argireline (Acetyl Hexapeptide-8) |
|---|---|---|
| INCI Name | Dipeptide Diaminobutyroyl Benzylamide Diacetate | Acetyl Hexapeptide-8 |
| CAS Number | 823202-99-9 | 616204-22-9 |
| Peptide Type | Dipeptide (synthetic snake venom peptide) | Hexapeptide (SNAP-25 mimic) |
| Target | Muscarinic ACh receptors (mAChR antagonist) | SNAP-25 protein (inhibits ACh exocytosis) |
| Mechanism | Blocks receptor binding | Blocks neurotransmitter release |
| In vitro contraction inhibition | Up to 82% at 0.5 mM | Up to 80% at 10 mM |
| In vivo wrinkle reduction (28 days) | ~21% wrinkle depth reduction | ~17–30% (varies by study) |
| Typical use level | 0.5–5% | 5–10% |
| Solubility | Water-soluble | Water-soluble |
| Skin feel | Light, non-tacky | Can feel slightly film-forming at higher % |
A few things I’ve noticed from working with both:
- Potency edge: Syn-Ake is the stronger actor in vitro (IC₅₀ ~0.05 mM vs. Argireline’s ~5 mM — that’s roughly a 100x difference). That doesn’t automatically mean better clinical results, but it does mean you need less of it in your formula to get an effect.
- Complementary mechanisms: Since Syn-Ake blocks the receptor and Argireline blocks the neurotransmitter release, combining them isn’t just marketing fluff. You’re genuinely hitting the signal at two different points in the pathway. I’ve seen brands do this successfully.
- Cost: Both sit in the premium cosmetic peptide tier. Syn-Ake usually runs a bit higher per kilogram because of the more involved synthesis (that benzylamide group adds complexity).
- Marketing angle: “Snake venom peptide” sells. There’s no way around it — Syn-Ake has a better story for consumer marketing than “acetyl hexapeptide.” That matters for product positioning, even if it shouldn’t drive formulation decisions.
Formulation Considerations
From a practical formulating standpoint, dipeptide diaminobutyroyl benzylamide diacetate isn’t difficult to work with:
Stability
Syn-Ake is stable at pH 4.5–6.5, which fits comfortably within most serum and cream systems. It plays nice with common preservatives and emulsifiers. The one thing to watch is heat — don’t expose it to temperatures above 40°C for extended periods. In emulsion production, add it during the cool-down phase, ideally below 35°C.
Best Formats
- Serums: This is where Syn-Ake performs best. A 3–4% serum applied twice daily to target areas is the most effective approach I’ve seen.
- Eye creams: A natural fit — crow’s feet are exactly the kind of expression line this peptide addresses. Use 1–3% for the thinner eye-area skin.
- Day/night creams: 0.5–2% works fine here, especially as part of a broader anti-aging formulation with ingredients like hyaluronic acid or niacinamide.
Worth Pairing With
- Argireline: The dual-mechanism approach I mentioned above. Legitimately synergistic, not just label decoration.
- Hyaluronic acid: Gives you immediate hydration plumping while Syn-Ake works on the longer-term contraction side. Good complementary timing.
- Matrixyl (Palmitoyl Pentapeptide-4): Matrixyl stimulates collagen synthesis — a different anti-aging pathway entirely. Your formula handles expression lines (Syn-Ake) and skin structure (Matrixyl) simultaneously.
- Vitamin C derivatives: Antioxidant protection and brightening alongside the anti-wrinkle mechanism. Standard multi-benefit pairing.
Safety Profile
The safety data is pretty straightforward and should put to rest any concerns about the “snake venom” label:
- No cytotoxicity at concentrations up to 1% in keratinocyte cultures — well above what any finished product would contain.
- No irritation or sensitization was reported in the human clinical trials.
- Not classified as a neurotoxin by any regulatory body. It modulates receptor activity locally with no evidence of systemic absorption.
- Fully compliant with EU Cosmetics Regulation (EC) No 1223/2009 — no restricted substance issues.
I get why consumers might be nervous about “snake venom” on their ingredient list. But the synthetic peptide only mimics a small portion of the waglerin-1 binding motif. The biological activity is highly specific to local topical application. You’d have more reason to be concerned about the alcohol in your toner.
Sourcing Dipeptide Diaminobutyroyl Benzylamide Diacetate
If you’re formulating with Syn-Ake or considering it, here’s what I’d actually evaluate in a supplier:
- Purity: Accept ≥95% by HPLC. Anything below that and you’re dealing with synthesis impurities that can mess with both efficacy and your formulation’s shelf life.
- Documentation: COA with HPLC, NMR data for every batch. Stability data and microbial testing should be included without having to ask.
- Batch consistency: Since Syn-Ake is fully synthetic, batch-to-batch variation should be minimal. If a supplier can’t show you tracking data across batches, that’s a red flag.
Frequently Asked Questions
Can dipeptide diaminobutyroyl benzylamide diacetate really replace Botox?
Short answer: no. Botox produces 60–80% reduction in glabellar line severity by chemically denervating the muscle for 3–6 months. Syn-Ake delivers around 21% wrinkle depth reduction over 28 days through a much gentler receptor-blocking mechanism. They’re in completely different efficacy categories. That said, Syn-Ake has a real role — it works well as a daily-use topical between Botox sessions, or as a non-invasive option for consumers who aren’t comfortable with injections. The results won’t be as dramatic, but they’re real and measurable. Just set expectations for your product claims.
What concentration of Syn-Ake should I use in my formulation?
For leave-on serums and creams targeting expression lines, 3–4% is the sweet spot. The clinical trial used 4% and got clean, measurable results without any irritation issues. For eye-area products, dial it back to 1–2% — thinner skin needs lower active concentrations. Below 0.5%, you’re probably not going to see a statistically meaningful effect. Above 5%, diminishing returns kick in, and you might run into slight tackiness or crystallization issues at cold temperatures. One thing that matters more than concentration: your delivery system. A well-formulated serum with good skin penetration will outperform the same percentage in a basic cream.
Syn-Ake vs Argireline — which should I choose for my anti-wrinkle serum?
They’re both legitimate, well-studied peptides, but they work through different mechanisms. Syn-Ake (dipeptide diaminobutyroyl benzylamide diacetate) blocks the acetylcholine receptor on the muscle surface. Argireline (Acetyl Hexapeptide-8) blocks acetylcholine release itself. Clinically, both land in the 17–30% wrinkle reduction range at 28 days — the exact numbers bounce around between studies. Syn-Ake is more potent at lower concentrations in vitro and typically costs more per kilogram. Argireline has a longer track record, and most formulators are more familiar with it. My honest recommendation? Use both. Their complementary mechanisms aren’t just theory — hitting the neuromuscular signal at two separate points genuinely produces better results than either one alone.
Final Thoughts
Dipeptide diaminobutyroyl benzylamide diacetate (Syn-Ake) has earned its place in the cosmetic peptide toolkit. It’s got a defined mechanism, published clinical data showing ~21% wrinkle reduction at 28 days, and a clean safety profile. It’s not going to replace Botox — anyone claiming otherwise is overselling — but for formulators building non-invasive anti-aging products, it’s a credible, well-supported option.
The trick is using it at the right concentration, in a compatible base, with honest marketing claims. If you’re sourcing Syn-Ake for your next project, MonuoChem supplies dipeptide diaminobutyroyl benzylamide diacetate with full analytical documentation, batch-to-batch tracking, and regulatory support for major markets.